| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5502938 | Journal of the Neurological Sciences | 2017 | 20 Pages |
Abstract
Rituximab treatment on NMO and NMOSD patients showed significant improvement in disability and relapse-rate without any significant adverse effects.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
M.E. Evangelopoulos, E. Andreadou, G. Koutsis, V. Koutoulidis, M. Anagnostouli, P. Katsika, D.S. Evangelopoulos, I. Evdokimidis, C. Kilidireas,